Epidemiology of senile prostatic enlargement among elderly men in Arar, Kingdom of Saudi Arabia
Keywords:
Senile prostatic enlargement; Benign prostatic hyperplasia; Prevalence; Arar; Saudi ArabiaAbstract
Background and aim: Senile prostatic enlargement due to benign prostatic hyperplasia (BPH) is a common problem among older men, and is responsible for considerable disability. This study was conducted to determine the prevalence and determinants of the clinically diagnosed prostatic enlargement among elderly men in Arar, Northern Saudi Arabia.
Methods: This cross-sectional study was carried out on all consented elderly males attending the outpatient clinic of the urology department of Arar Central Hospital from February 2017 to July 30, 2017. Each participant underwent a general examination and digital per rectal to detect general chronic diseases, obesity and prostatic enlargement. Data were analyzed by SPSS version 16, using descriptive statistics and Chi-squared test.
Results: Among 81 elderly male participants in the study, 19.8% had clinically diagnosed senile prostatic enlargement (SPE) and 3.7% had prostatic tumors. There was significant relation between SPE and age as 6.2% of cases were 60-69 years, 43.8% were 70-79 years and 44.0% were 80 years or more (p<0.05). There was also significant relation between SPE and obesity as 62.5% of cases were obese and 37.5% were non obese (p<0.05). There was no significant relation with marital status, smoking or diabetes mellitus (p<0.05).
Conclusion: Senile prostatic enlargement is one of the significant important issues in public health in Arar city, Northern Saudi Arabia. The prevalence of this condition reaches 19.3%, thereby placing even greater burden on the quality of life of the elderly and on the health system in the region.
References
Roehrborn CG. Benign Prostatic Hyperplasia: An Overview. Rev Urol. 2005; 7(Suppl 9): S3-14 PMID:
, PMCID: PMC1477638.
McVary KT, Roehrborn CG, Avins AL, Barry MJ, Bruskewitz RC, Donnell RF, et al. Update on AUA
guideline on the management of benign prostatic hyperplasia. J Urol. 2011; 185: 1793–803. doi:
1016/j.juro.2011.01.074. PMID: 21420124.
Barry MJ, Fowler FJ Jr, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, et al. The American
UrologicalAssociation symptom index for benign prostatic hyperplasia. The Measurement Committee of
the American Urological Association. J Urol. 1992; 148(5): 1549-57. doi: 10.1016/S0022-5347(17)36966- 5. PMID: 1279218.
Lower urinary tract symptoms in men: management. NICE. 2010.
White JM, O'Brien DP. Incontinence and Stream Abnormalities. 3rd edition. Boston: Butterworths; 1990.
PMID: 21250138.
Urge incontinence. Medline Plus. US National Library of Medicine. 2015.
Patel ND1, Parsons JK. Epidemiology and Etiology of Benign Prostatic Hyperplasia and Bladder Outlet
Obstruction. Indian J Urol. 2014; 30(2): 170-6. doi: 10.4103/0970-1591.126900. PMID: 24744516,
PMCID: PMC3989819.
Kapoor A. Benign prostatic hyperplasia (BPH) management in the primary care setting. Can J Urol. 2012;
Suppl 1: 10-7. PMID: 23089343.
Guess HA, Arrighi HM, Metter EJ, Fozard JL. Cumulative prevalence of prostatism matches the autopsy
prevalence of benign prostatic hyperplasia. Prostate. 1990; 17(3): 241. doi: 10.1002/pros.2990170308.
PMID: 1700403.
Kok ET, Schouten BW, Bohnen AM, Groeneveld FP, Thomas S, Bosch JL. Risk factors for lower urinary
tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy
aging men: The Krimpen study. J Urol. 2009; 181: 710–6. doi: 10.1016/j.juro.2008.10.025. PMID:
Jacobsen SJ, Jacobson DJ, Girman CJ, Roberts RO, Rhodes T, Guess HA, et al. Natural history of
prostatism: Risk factors for acute urinary retention. J Urol. 1997; 158: 481–7. doi: 10.1016/S0022- 5347(01)64508-7. PMID: 9224329.
Bosch JL, Hop WC, Kirkels WJ, Schröder FH. Natural history of benign prostatic hyperplasia: Appropriate
case definition and estimation of its prevalence in the community. Urology. 1995; 46: 34–40. doi:
1016/S0090-4295(99)80248-9. PMID: 7544515.
Fong YK, Milani S, Djavan B. Natural history and clinical predictors of clinical progression in benign
prostatic hyperplasia. Curr Opin Urol. 2005; 15: 35–8. doi: 10.1097/00042307-200501000-00009. PMID:
Guess HA, Arrighi HM, Metter EJ, Fozard JL. Cumulative prevalence of prostatism matches the autopsy
prevalence of benign prostatic hyperplasia. Prostate. 1990; 17: 241–6. doi: 10.1002/pros.2990170308.
PMID: 1700403.
Tantiwong A, Nuanyong C, Vanprapar N, Swasdipala P, Chittapraphai S. Benign prostatic hyperplasia in
elderly Thai men in an urban community: The prevalence, natural history and health related behavior. J
Med Assoc Thai. 2002; 85: 356–60. PMID: 12117026.
Wei JT, Calhoun E, Jacobsen SJ. Urologic diseases in America project: Benign prostatic hyperplasia. J
Urol. 2005; 173: 1256–61. doi: 10.1097/01.ju.0000155709.37840.fe. PMID: 15758764.
Egan KB. The Epidemiology of Benign Prostatic Hyperplasia Associated with Lower Urinary Tract
Symptoms: Prevalence and Incident Rates. Urol Clin North Am. 2016: 43(3): 289-97. doi:
1016/j.ucl.2016.04.001. PMID: 27476122.
Alghamidi IG, Hussain II, Alghamdi MS, El-Sheemy MA. The incidence rate of prostate cancer in Saudi
Arabia: an observational descriptive epidemiological analysis of data from the Saudi Cancer Registry
–2008. Hematol Oncol Stem Cell Ther. 2014; 7(1): 18-26. doi: 10.1016/j.hemonc.2013.10.001. PMID:
Al-Abdin OZ, Rabah DM, Aprikian A. Differences in prostate cancer detection between Canadian and
Saudi populations. Braz J Med Biol Res. 2013; 46: 539–45. doi: 10.1590/1414-431X20132757. PMID:
, PMCID: PMC3854441.
Barry MJ, Fowler FJ Jr, Bin L, Pitts JC 3rd, Harris CJ, Mulley AG Jr. The natural history of patients with
benign prostatic hyperplasia as diagnosed by North American urologists. J Urol. 1997; 157: 10–4. doi:
1016/S0022-5347(01)65267-4. PMID: 8976204.
Chokkalingam AP, Yeboah ED, Demarzo A, Netto G, Yu K, Biritwum RB, et al. Prevalence of BPH and
lower urinary tract symptoms in West Africans. Prostate Cancer Prostatic Dis. 2012; 15(2): 170-6. doi:
1038/pcan.2011.43. PMID: 21912428.
Naslund MJ, Gilsenan AW, Midkiff KD, Bown A, Wolford ET, Wang J. Prevalence of lower urinary tract
symptoms and prostate enlargement in the primary care setting. Int J Clin Pract. 2007; 61: 1437–45. doi:
1111/j.1742-1241.2007.01508.x. PMID: 17686091.
Guess HA, Arrighi HM, Metter EJ, Fozard JL. Cumulative prevalence of prostatism matches the autopsy
prevalence of benign prostatic hyperplasia. Prostate. 1990; 17: 241–6. doi: 10.1002/pros.2990170308.
PMID: 1700403.
Parsons JK, Sarma AV, McVary K, Wei JT. Obesity and benign prostatic hyperplasia: Clinical
connections, emerging etiological paradigms and future directions. J Urol. 2013; 189: S102–6. doi:
1016/j.juro.2012.11.029. PMID: 23234610.
Sarma AV, Parsons JK, McVary K, Wei JT. Diabetes and benign prostatic hyperplasia/lower urinary tract
symptoms--what do we know? J Urol. 2009; 182: S32–7. doi: 10.1016/j.juro.2009.07.088. PMID:
Parsons JK, Bergstrom J, Barrett-Connor E. Lipids, lipoproteins and the risk of benign prostatic hyperplasia
in community-dwelling men. BJU Int. 2008; 101: 313–8. doi: 10.1111/j.1464-410X.2007.07332.x. PMID:
, PMCID: PMC2647139.
Gupta A, Gupta S, Pavuk M, Roehrborn CG. Anthropometric and metabolic factors and risk of benign
prostatic hyperplasia: A prospective cohort study of Air Force veterans. Urology. 2006; 68: 1198–205. doi:
1016/j.urology.2006.09.034. PMID: 17169643.
Parsons JK. Modifiable risk factors for benign prostatic hyperplasia and lower urinary tract symptoms:
New approaches to old problems. J Urol. 2007; 178: 395–401. doi: 10.1016/j.juro.2007.03.103. PMID:
Published
Issue
Section
License
Copyright (c) 2020 KNOWLEDGE KINGDOM PUBLISHING
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
